COL4A3 and chronic kidney disease: One week of DMP1 injections to 129 Sv Col4a3−/− mice with advanced CKD (Fig. 2j–k) or treatment of 129 Sv Col4a3−/− primary osteoblasts with DMP1 in vitro (data not shown) led to similar results, including full correction of the bone mineralization defects.